26,450 Illumina, Inc. $ILMN Shares Sold by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 3.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 803,843 shares of the life sciences company’s stock after selling 26,450 shares during the period. Illumina makes up about 2.8% of Letko Brosseau & Associates Inc.’s holdings, making the stock its 9th biggest position. Letko Brosseau & Associates Inc. owned 0.53% of Illumina worth $219,996,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Illumina in the second quarter worth approximately $3,374,423,000. WCM Investment Management LLC raised its stake in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA bought a new stake in shares of Illumina in the 2nd quarter worth approximately $617,981,000. Janus Henderson Group PLC lifted its holdings in shares of Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after acquiring an additional 29,094 shares during the last quarter. Finally, Southpoint Capital Advisors LP boosted its stake in shares of Illumina by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock valued at $258,846,000 after purchasing an additional 349,536 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Recent Illumina Headlines

These are some of the ILMN headlines that stood out recently:

  • Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
  • Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
  • Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing

Analyst Ratings Changes

A number of equities analysts recently commented on ILMN shares. Barclays lifted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research report on Wednesday, October 7th. Argus raised their price objective on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Canaccord Genuity Group lifted their price objective on Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, October 19th. Leerink Partners boosted their target price on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Finally, Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and an average price target of $244.24.

View Our Latest Stock Analysis on Illumina

Illumina Price Performance

Illumina stock opened at $209.55 on Friday. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The firm’s fifty day moving average is $249.32 and its 200 day moving average is $179.36. The company has a market cap of $31.68 billion, a price-to-earnings ratio of 40.56, a PEG ratio of 2.89 and a beta of 1.46.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter in the prior year, the firm posted $1.34 EPS. Illumina’s quarterly revenue was up 4.2% compared to the same quarter last year. Sell-side analysts forecast that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, Director Keith A. Meister sold 98,833 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the transaction, the director owned 208,826 shares of the company’s stock, valued at approximately $45,288,094.62. This represents a 32.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Scott D. Ericksen sold 267 shares of the stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total value of $58,141.92. Following the completion of the sale, the chief accounting officer owned 14,029 shares in the company, valued at approximately $3,054,955.04. The trade was a 1.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,881,899 shares of company stock worth $415,905,954 over the last three months. 2.90% of the stock is currently owned by corporate insiders.

Illumina Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Featured Articles

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.